No controlled human trial has published a side-effect rate or safety profile for Selank. Here is what is actually known instead, and what that gap does and does not tell you.
No completed controlled human trial has shown which dose works for Selank. There is no study-backed human dosing program to publish. Animal quantities are not converted into a human recommendation.
Because no controlled human safety profile has been published for this compound, there is no evidence-based list of warning signs specific to it. That removes the early warning, not the risk. Any new, severe or lasting symptom belongs with a clinician. Tell them exactly what was taken.
EmergencySome symptoms should not wait for an appointment. Call emergency services (911 in the US) if they are severe, getting worse fast, or involve trouble breathing, chest pain, fainting or confusion.
Selank is a peptide seven amino acids long. It is a small immune fragment called tuftsin, with a tail added to slow its breakdown. Sellers market it for anxiety, stress and calm focus.
Russian groups gave it to patients with anxiety disorders and compared it with two older sedatives. Those studies never said how much anyone received. No source gives a human dose. English reviews describe it as well tolerated, but they trace that claim to an experiment in rats.
At a glance
Common reactions listed
None published
Serious reactions listed
None published
Boxed warning
No label exists
Strongest source
no human dose shown to work
Nothing measured is not the same as nothing to find — the section below is about that difference.
3Read deeperTiming, evidence limits, and product context
Why there is no Selank side-effect profile here
There is no side-effect table on this page because there is no controlled human safety profile to build one from — and an empty table is more honest than a plausible one.
A published side-effect profile is not a summary of what people have noticed. It is the output of a specific process: a controlled trial enrolls a defined group and records every event, whether or not it looks related. It compares those rates against a control group, then publishes the result against a plan registered before the first dose. Where that process has not produced a profile, the output does not exist. Nothing stands in for it — not seller literature, not clinic protocols, not forum threads.
So the absence says something about the evidence, not about the compound. A profile nobody has measured is not a clean profile; it is an unmeasured one. Those two get confused constantly, and the confusion always runs in the direction that flatters the compound.
It is worth being blunt about the asymmetry. Rare and serious reactions are exactly the ones that scattered, self-reported experience is worst at catching. They are uncommon by definition, they can take time to appear, and they are easy to blame on something else.
The people who get them are also the least likely to come back and post an update. What shows up first in an unstudied compound is the mild and the immediate. That is a fact about how the reports get collected, not evidence about the compound.
The missing profile takes the rest of the scaffolding with it. With no approved label there is no list of who should avoid it, no documented interactions and no monitoring plan. There is no ceiling dose, and no channel carrying reports back to a regulator. Anyone taking an unapproved compound is outside all of those at once — and silence from a system that does not exist is not reassurance.
Selank studies report side effects but leave safety questions open
Small studies in people with anxiety disorders assessed Selank’s effects and how well people handled it. The available abstracts omit the dose and do not provide a complete table of adverse-event rates. They cannot establish long-term safety or a reliable rate for a particular side effect.
Human side-effect reports exist
A comparison with phenazepam assessed both anxiety symptoms and side effects. Another study examined Selank added to phenazepam. These are human observations, not just animal findings.
The abstracts do not provide the information needed to calculate a reliable rate for each adverse effect. A report without event counts should not be turned into a percentage.
Small treatment groups and limited follow-up also leave questions about uncommon events and long-term use. A favorable report cannot rule out other harms.
Combination-treatment effects need their context
One study asked whether adding Selank changed unwanted effects during phenazepam treatment. It reported fewer of some effects with the combination.
Those observations concern the combined treatment and its comparison group. They should not be presented as a list of effects caused by Selank alone.
The result also cannot predict what would happen with a different preparation, amount or treatment duration. Those details need their own evidence.
The available abstracts omit the dose
The published abstracts identify the patient groups, comparators and symptom scales. They do not state how much Selank participants received.
Without that amount and a complete treatment protocol, the studies cannot provide a dosing schedule. A reported anxiety result does not fill in the missing details.
The human findings still belong in the evidence summary. Their limits should be stated alongside them, rather than treating incomplete reporting as proof that no study took place.
What the absence does and does not mean
Four readings of an empty safety record go around. Each one turns a missing measurement into reassurance.
The claim
What the evidence shows
Nothing serious has been reported.
Nothing has been systematically collected. A report needs a system that receives it, strips out duplicates and counts it. For an unapproved compound there is no such system, so silence is what you would get either way.
The studies look clean.
The published work is overwhelmingly in animals or too small and uncontrolled to produce a safety rate. Animal findings do not carry over to people at human doses over human timescales, and uncontrolled exposure supplies no comparison group or denominator.
People have used it for years.
Informal use is not monitoring. Years of unmeasured use produce familiarity and confidence. They do not produce a denominator, a comparison group, or a rate.
People seem to handle it well.
How well people handle a compound is measured against a control group. Without that comparison, the claim is only the writer’s impression.
No human safety profile has been published for this compound. If that changes, the results should be reported with the study size, comparison group and citation—not filled in with assumptions.
Common questions
Does Selank have known side effects?
No controlled human study has published a side-effect rate or safety profile. That describes the missing evidence, not the compound: unmeasured does not mean safe.
Is Selank safe?
The published human evidence cannot answer that either way. Reliable safety estimates need systematic collection, a total number treated and a comparison group; none is available here.
What should someone do about symptoms after taking an unapproved compound?
Take the symptom to a clinician, and say exactly what was taken, how much and for how long. Clinicians assess symptoms without needing an approved label to exist, and leaving out the detail removes the one piece of context that changes what they look for.
Related
The schedule these reactions were recorded against, the comparisons, and the sourcing rules behind every grade on this page.